VJHemOnc is committed to improving our service to you

ASH 2019 | Should we act therapeutically on MRD positivity in AML?

VJHemOnc is committed to improving our service to you

Christoph Röllig

Christoph Röllig, MD, MSc, University Hospital Carl Gustav Carus, Dresden, Germany, discusses the measurement of residual disease in acute myeloid leukemia (AML), and the question of whether we should act therapeutically on MRD positivity in AML. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter